{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:35:04Z","timestamp":1787826904449,"version":"build-2784847793"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Integrase strand transfer inhibitor\u2013based regimens are recommended for first-line therapy in human immunodeficiency virus type 2 (HIV-2). Nonetheless, dolutegravir (DTG) clinical trial data are lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a phase 2, single-arm, open-label trial to evaluate the safety and efficacy of a triple therapy regimen that included DTG in persons with HIV-2 (PWHIV-2) in Portugal. Treatment-naive adults receive DTG in combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs). Treatment efficacy was evaluated by the proportion of patients who achieved a plasma viral load (pVL) &amp;lt;40 copies\/mL and\/or by the change from baseline in CD4+ T-cell count and in CD4\/CD8 ratio at week 48.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 30 patients were enrolled (22 women; median age, 55 years). At baseline, 17 (56.7%) individuals were viremic (median, pVL 190 copies\/mL; interquartile range [IQR], 99\u2013445). The median CD4 count was 438 cells\/\u03bcL (IQR, 335\u2013605), and the CD4\/CD8 ratio was 0.8. Three patients discontinued the study. At week 48, all participants (27) had pVL &amp;lt;40 copies\/mL. No virological failures were observed. Mean changes in CD4 count and CD4\/CD8 ratio at week 48 were 95.59 cells\/\u00b5L (95% confidence interval [CI], 28\u2013163) and 0.32 (95% CI, .19 to .46). The most common drug-related adverse events were headache and nausea. One participant discontinued due to central nervous system symptoms. No serious adverse events were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>DTG plus 2 NRTIs is safe and effective as first-line treatment for PWHIV-2 with a tolerability profile previously known. No virological failures were observed that suggest a high potency of DTG in HIV-2 as occurs in HIV-1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>M NCT 03224338.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad339","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T12:51:30Z","timestamp":1686228690000},"page":"740-748","source":"Crossref","is-referenced-by-count":12,"title":["Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study"],"prefix":"10.1093","volume":"77","author":[{"given":"Patr\u00edcia","family":"Pacheco","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Professor Doutor Fernando Fonseca , Amadora , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Marques","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Garcia de Orta , Almada , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Beatriz \u00c2ngelo , Loures , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Mansinho","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Egas Moniz , Lisboa , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Maltez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Curry Cabral , Lisboa , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Janeiro","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Santa Maria , Lisboa , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia","family":"Franco","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Santa Maria , Lisboa , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diva","family":"Trigo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Professor Doutor Fernando Fonseca , Amadora , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Batista","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Professor Doutor Fernando Fonseca , Amadora , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"Duque","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Professor Doutor Fernando Fonseca , Amadora , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o","family":"Lopes","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Professor Doutor Fernando Fonseca , Amadora , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o","family":"Aleixo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Garcia de Orta , Almada , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rita","family":"Silva","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Beatriz \u00c2ngelo , Loures , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Tavares","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Beatriz \u00c2ngelo , Loures , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Alves","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Egas Moniz , Lisboa , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Peres","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Egas Moniz , Lisboa , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"P\u00f3voas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Curry Cabral , Lisboa , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lino","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Curry Cabral , Lisboa , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perp\u00e9tua","family":"Gomes","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory, Hospital Egas Moniz , Lisboa , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e2nia","family":"Ara\u00fajo","sequence":"additional","affiliation":[{"name":"BlueClinical Ltd , Matosinhos , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Lopes","sequence":"additional","affiliation":[{"name":"BlueClinical Ltd , Matosinhos , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"2023091120385856500_ciad339-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.35","article-title":"HIV infection","volume":"1","author":"Deeks","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2023091120385856500_ciad339-B2","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/QAD.0b013e32830edd44","article-title":"A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa","volume":"22","author":"Gottlieb","year":"2008","journal-title":"AIDS"},{"key":"2023091120385856500_ciad339-B3","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/cid\/ciq248","article-title":"Update on human immunodeficiency virus (HIV)-2 infection","volume":"52","author":"Campbell-Yesufu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023091120385856500_ciad339-B4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000332025","article-title":"Special aspects of the treatment of HIV-2-infected patients","volume":"55","author":"Camacho","year":"2012","journal-title":"Intervirology"},{"key":"2023091120385856500_ciad339-B5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S2055-6640(20)30300-9","article-title":"Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection","volume":"3","author":"Saleh","year":"2017","journal-title":"J Virus Erad"},{"key":"2023091120385856500_ciad339-B6","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/cid\/cir123","article-title":"Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: the ACHI(E)V(2E) Collaboration Study Group","volume":"52","author":"Benard","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023091120385856500_ciad339-B7","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1097\/QAD.0b013e32832949f0","article-title":"Good response to lopinavir\/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients","volume":"23","author":"B\u00e9nard","year":"2009","journal-title":"AIDS"},{"key":"2023091120385856500_ciad339-B8","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/00002030-200317003-00008","article-title":"Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients","volume":"17","author":"Van der Ende","year":"2003","journal-title":"AIDS"},{"key":"2023091120385856500_ciad339-B9","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/cid\/ciaa275","article-title":"Human immunodeficiency virus\u20132 (HIV-2): a summary of the present standard of care and treatment options for individuals living with HIV-2 in Western Europe","volume":"72","author":"Berzow","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023091120385856500_ciad339-B10","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2023091120385856500_ciad339-B11","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1016\/S2352-3018(18)30094-8","article-title":"90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2","volume":"5","author":"Gottlieb","year":"2018","journal-title":"Lancet HIV"},{"key":"2023091120385856500_ciad339-B12","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3851\/IMP2303","article-title":"The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series","volume":"17","author":"Peterson","year":"2012","journal-title":"Antivir Ther"},{"key":"2023091120385856500_ciad339-B13","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/cid\/ciy245","article-title":"First-line raltegravir\/emtricitabine\/tenofovir combination in human immunodeficiency virus type 2 (HIV-2) infection: a phase 2, noncomparative trial (ANRS) 159 HIV-2","volume":"67","author":"Matheron","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023091120385856500_ciad339-B14","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/cid\/ciy324","article-title":"A trial of a single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for the initial treatment of human immunodeficiency virus type 2 infection in a resource-limited setting: 48-week results from Senegal, West Africa","volume":"67","author":"Ba","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023091120385856500_ciad339-B15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12977-015-0146-8","article-title":"In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2","volume":"12","author":"Smith","year":"2015","journal-title":"Retrovirology"},{"key":"2023091120385856500_ciad339-B16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcv.2015.01.001","article-title":"Dolutegravir for the treatment of HIV-2 infection","volume":"64","author":"Trevi\u00f1o","year":"2015","journal-title":"J Clin Virol"},{"key":"2023091120385856500_ciad339-B17","first-page":"1521","article-title":"Dolutegravir in HIV-2\u2013infected subjects with resistant virus to first-line integrase inhibitors from the French named patient program","volume":"60","author":"Descamps","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023091120385856500_ciad339-B18","author":"World Health Organization","year":"2018"},{"key":"2023091120385856500_ciad339-B19"},{"key":"2023091120385856500_ciad339-B20","author":"Division of AIDS","year":"2017"},{"key":"2023091120385856500_ciad339-B21","year":"2019"},{"key":"2023091120385856500_ciad339-B22","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/jac\/dkx210","article-title":"CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study","volume":"72","author":"Wittkop","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023091120385856500_ciad339-B23","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad339\/50743730\/ciad339.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/5\/740\/51515959\/ciad339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/5\/740\/51515959\/ciad339.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T21:31:46Z","timestamp":1694467906000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/5\/740\/7192102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,6,8]]},"published-print":{"date-parts":[[2023,9,11]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad339","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,6,8]]}}}